Cytokinetics (CYTK) Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. META
5. MU
6. ACN
7. NVDA
8. BLZE
9. IBM
10. PRIM

Go back to Cytokinetics (CYTK) Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
CYTOKINETICS (NASDAQ: CYTK) Delayed: 79.95 +0.78 (0.99%)
Previous Close $79.17    52 Week High $13.18 
Open $78.99    52 Week Low $6.00 
Day High $80.40    P/E N/A 
Day Low $78.27    EPS $-1.24 
Volume 1,343,961